| PDA0107 | Youth perinatal HIV-associated cognitive impairment: Associations with childhood trauma | Poster exhibition | A13 |
| PDA0202 | High Y-chromosome DNA concentrations are associated with increased cervical cytokine concentrations and activated cervical HIV target cell frequencies | Poster exhibition | A8 |
| PDA0203 | CyTOF analysis reveals that HIV-1 upregulates expression of multiple RNA and DNA sensors in subsets of primary CD4+ T cells | Poster exhibition | A9 |
| PDA0205 | TILRR modulates production of proinflammatory cytokines and promote leukocytes migration and may be a novel target to prevent HIV-1 vaginal infection | Poster exhibition | A5 |
| PDA0206 | Th17 cells are early targets of SIV during acute infection in rhesus macaque vaginal challenge model | Poster exhibition | A9 |
| PDA0207 | Interferon-a modulates the host glycosylation machinery during treated HIV infection | Poster exhibition | A24 |
| PDB0102 | Time to viral rebound after interruption of modern antiretroviral therapies | Poster exhibition | B40 |
| PDB0103 | Is DTG+3TC effective and safe in clinical practice? Evidence from real world data | Poster exhibition | B30 |
| PDB0104 | Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis | Poster exhibition | B30 |
| PDB0105 | Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR) | Poster exhibition | B32 |